Novartis’ Gilenya woes deepen as Dusseldorf court overturns preliminary injunction
Despite unusual circumstances of the fingolimod disputes, the cases highlight some of the potential pitfalls facing pharma patentees in Germany and elsewhere in Europe
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.